Non-coding RNAs as theranostics in human cancers

Journal of Cellular Biochemistry

Volumn 113, Issue 5, 2012, Pages 1451-1459

  Redis, Roxana S ^a,b   Berindan Neagoe, Ioana ^a,c   Pop, Victor I ^a   Calin, George A ^b  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

Author keywords

CANCER; miRNA; THERAPY

Indexed keywords

ADENOVIRUS VECTOR; LOCKED NUCLEIC ACID; MICRORNA; NANOPARTICLE; RNA ANTIBODY; UNTRANSLATED RNA;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; COLON CANCER; GENE TARGETING; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; NANOTECHNOLOGY; NONHODGKIN LYMPHOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; THERANOSTICS;

DEPENDOVIRUS; DRUG RESISTANCE, NEOPLASM; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HUMANS; INDIVIDUALIZED MEDICINE; MICRORNAS; MOLECULAR MIMICRY; NANOPARTICLES; NEOPLASMS; OLIGONUCLEOTIDES; ONCOGENES; RNA, ANTISENSE; RNA, NEOPLASM; RNA, UNTRANSLATED;

EID: 84859022851     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24038     Document Type: Article

References (76)

1. Amaral PP, Mattick JS,. 2008. Noncoding RNA in development. Mamm Genome 19: 454-492.
2. Bader AG, Brown D, Winkler M,. 2010. The promise of microRNA replacement therapy. Cancer REs 70: 7027-7030.
3. Bai H, Xu R, Cao Z, Wei D, Wang C,. 2011. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett 585: 402-408.
4. Bartel DP,. 2004. MicroRNAs: Genomics, biogenesis, mechanism and function. Cell 116: 281-297.
5. Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM,. 2009. MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS 276: 6689-6700.
6. Bourguignon LY, Spevak CC, Wong CC, Xia W, Gilad E,. 2009. Hyaluronan-CD44 interaction with protein kinase C (epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 284: 26533-26546.
7. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Alder H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM,. 2002. Frequent deletions and downregulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529. (Pubitemid 35403967)
8. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM,. 2004. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancer. Proc Natl Acad Sci USA 101: 2999-3004. (Pubitemid 38327724)
9. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, Allgayer H,. 2010. Loss of miR-200c expression induces an aggressive, invasive and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8: 1207-1216.
10. Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano A, Bozzoni I,. 2011. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 147: 358-369.
11. Chan JA, Krichevsky AM, Kosik KS,. 2005. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029-6033. (Pubitemid 40994386)
12. Chen Y, Zhu X, Zhang X, Liu B, Huang L,. 2010. Nanoparticles modified with tumortargeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 18: 1650-1656.
13. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Ageilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, KIpps TJ, Negrini M, Croce CM,. 2005. miR-15 and miR-16 induce apoptosis by targeting BCL-2. Proc Natl Acad Sci USA 102: 13944-13949. (Pubitemid 41377683)
14. Di Leva G, Calin GA, Croce CM,. 2006. MicroRNAs: Fundamental facts and involvement in human diseases. Birth Defects Res C Embryol Today 78: 180-189. (Pubitemid 44222856)
15. Duan W, Gao L, Wu X, Wang L, Nana-Sinkam SP, Otterson GA, Villalona-Calero MA,. 2010. MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network. Int J Cancer 127: 313-320.
16. Ebert MS, Sharp PA,. 2010. MicroRNA sponges: Progress and possibilities. RNA 16: 2043-2050.
17. Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, Hedtjarn M, Hansen JB, Hansen HF, Straarup EM, McCullagh K, Kearney P, Kauppinen S,. 2008a. Antagonism of miR-122 in mice by systemically administered LNA-antimiR leads to upregulation of a large set of predicted target mRNAs in liver. Nuclei Acid Res 36: 1153-1162. (Pubitemid 351330933)
18. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjarn M, Hansen HF, Berger U, Gullans S, Kearney P, Sarnow P, Straarup EM, Kauppinen S,. 2008b. LNA-mediated microRNA silencing in non-human primates. Nature 452: 896-899. (Pubitemid 351550859)
19. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subraman A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP,. 2006. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3: 87-98.
20. Fabani MM, Gait MJ,. 2008. miR-122 targeting with LNA/20-O-methyl oligonucleotide mixers, peptide nucleotides (PNA) and PNA-peptide conjugates. RNA 14: 336-346. (Pubitemid 351171593)
21. Fabani MM, Abreu-Goodger C, Williams D, Lyons PA, Torres AG, Smith KGC, Enright AJ, Gait MJ, Vigorito E,. 2010. Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acid Res 38: 4466-4475.
22. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozzawa Y, Deguchi T, Ito M,. 2008. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cell. Biochem Biophys Res Commun 377: 114-119.
23. Gottesman MM,. 2002. Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627. (Pubitemid 34177898)
24. Gumireddy K, Young DD, Xiong X, Hogenesch JB, Huang Q, Deiters A,. 2008. Small-molecule inhibitors of microRNA miR-21 function. Angew Chem Int Ed 47: 7482-7484.
25. Guo F, Li Y, Liu Y, Wang J, Li Y, Li G,. 2010. Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. Acta Biochem Biophys Sin 42: 224-229.
26. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, Vijver MJ, Sukumar S, Chang HY,. 2010. Long-non coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464: 1071-1076.
27. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E, Olson EN,. 2010. Modulation of K-RAS dependent lung tumorigenesis by microRNA-21. Cancer Cell 1: 282-293.
28. He L, Thomas JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM,. 2005. A microRNA polycistron as a potential human oncogene. Nature 435: 828-833. (Pubitemid 40839734)
29. Jeon HM, Sohn YW, Oh SY, Kim SH, Beck S, Kim S, Kim H,. 2001. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res 71: 3410-3421.
30. Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thoms M, Berdel WE, Serve H, Muller-Tidow C,. 2003. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22: 8031-8041. (Pubitemid 37175867)
31. Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, Qin LX, Yang W, Wang HY, Tang ZY, Croce CM, Wang XW,. 2009. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50: 472-480.
32. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, Ambesi-Impiombato A, Califano A, Migliazza A, Bhagat G, Dalla-Favera R,. 2010. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukaemia. Cancer Cell 17: 28-40.
33. Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M,. 2010. miR-34a attenuates paclitaxelresistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanism. Prostate 70: 1501-1512.
34. Koshkin AA, Rajwanshi VK, Wengel J,. 1998. Novel convenient synthesys of LNA [2.2.1]bicycle nucleotides. Tetrahedron Lett 39: 4381-4384. (Pubitemid 28240070)
35. Kota J, Chivukula RR, O'Donnell KA,. 2009. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017.
36. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP,. 2008. Involvement of microRNA-451 in resistance of the MCF7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7: 2152-2159.
37. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M,. 2005. Silencing of microRNAs in vivo with antagomirs. Nature 438: 685-689.
38. Krutzfeldt J, Kuwajima S, Braich R, Rajeev KG, Pena J, Tuschl T, Manoharan M, Stoffel M,. 2007. Specificity, duplex degradation and subcellular localization of anatagomirs. Nucleic Acids Res 35: 2885-2892. (Pubitemid 47073627)
39. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T,. 2008. Suppression of non-small cell lung tumor development by the let-7 microRNA family. PNAS 105: 3903-3908. (Pubitemid 351723497)
40. Lennox KA, Behlke MA,. 2011. Chemical modification and design of antimiRNA oligonucleotides. Gene Ther. 18: 1111-1120.
41. Liu XQ, Song WJ, Sun TM, Zhang PZ, Wang J,. 2010. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol Phar 8: 250-259.
42. Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, Jiang Y, Kung HF, Lai L, Jiang BH,. 2011. MicroRNA-21 induced angiogenesis through AKT and ERK activation and HIF1A expression. PLoS ONE 6: e19139.
43. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazeva P, Diebold J, Hermeking H,. 2008. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7: 2591-2600.
44. Lwin T, Lin J, Choi YS, Zhang X, Moscinski LC, Wright KL, Sotomayar EM, Dalton WS, Tao J,. 2010. Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood 116: 5228-5236.
45. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson E, Teruya-Feldstein J, Bell GW, Weinberg RA,. 2010. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 28: 341-347.
46. Mattick JS,. 2001. Non-coding RNAs: The architects of eukaryotic complexity. EMBO Rep 2: 986-991. (Pubitemid 33130603)
47. Medina PP, Nolde M, Slack FJ,. 2010. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell-lymphoma. Nature 467: 86-90.
48. Meister G, Landthaler M, Dorsett Y, Tuschl T,. 2004. Sequence-specific inhibition of microRNA and siRNA-induced RNA silencing. RNA 10: 544-550. (Pubitemid 38241013)
49. Obad S, dos Santos CO, Petri A, Heidenbald M, Broom O, Ruse C, Fu C, Lindow M, Stenvang J, Straarup EM, Hansen HF, Koch T, Pappin D, Hannon GJ, Kauppinen S,. 2011. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43: 371-378.
50. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT,. 2005. c-Myc-regulated micro-RNAs modulate E2F1 expression. Nature 435: 839-843. (Pubitemid 40839736)
51. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ, He L,. 2009. miR-19 is a key oncogenic component of miR-17-92. Genes Dev 23: 2839-2849.
52. Orom UA, Kaupinnen S, Lund AH,. 2006. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 372: 137-141.
53. Ozpolat B, Sood AK, Lopez-Berestein G,. 2010. Nanomedicine based approaches for delivery of siRNA in cancer. J Intern Med 267: 44-53.
54. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatloukal K,. 2007. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 132: 330-342. (Pubitemid 46108730)
55. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Adler H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM,. 2006. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 66: 11590-11593. (Pubitemid 46094168)
56. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O,. 2010. Alterations of micro-RNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 127: 1785-1794.
57. Port M, Glaesener S, Ruf C, Riecke A, Bokemeyer C, Meineke V, Honecker F, Abend M,. 2011. Micro-RNA expression in cispaltin resistant germ cell tumor cell lines. Mol Cancer 10: 52-60.
58. Qian PX, Zuo Z, Wu ZS, Meng X, Li G, Wu Z, Zhang W, Tan S, Pandey V, Yao Y, Wang P, Zhao L, Wang J, Wu Q, Song E, Lobie P, Yin Z, Zhu T,. 2011. Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis. Cancer Res. DOI: 10.1158/0008-5472.
59. Rajaram V, Knezevich S, Bove KE, Perry A, Pfeifer JD,. 2007. DNA sequence of the translocation breakpoints in undifferentiated embryonal sarcoma arising in mesenchymal hamartoma of the liver harboring the t(11;19)(q11;q13.4) translocation. Genes Chromosome Cancer 46: 508-513. (Pubitemid 46449254)
60. Rao X, Leva GD, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP,. 2011. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 30: 1082-1097.
61. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Goswin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB,. 2010. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res 70: 6509-6515.
62. Shi SJ, Zhong ZR, Liu J, Zhang ZR, Sun X, Gong T,. 2011. Solid lipid nanoparticles loaded with anti-microRNA oligonuleotides (AMOs) for suppression of microRNA-21 functions in human lung cancer cells. Pharm Res. 29: 97-109.
63. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, Kawamata M, Kelnar K, Bader AG, Brown D, Ochiya T,. 2010. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18: 181-187.
64. Tano K, Mizuno R, Okada T, Rakwal R, Shibato J, Masuo Y, Ijiri K, Akimitsu N,. 2010. MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett 584: 4575-4580.
65. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H,. 2007. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. PNAS 104: 15472-15477. (Pubitemid 47502941)
66. Thomas JR, Hergenrother PJ,. 2008. Targeting RNA with small molecules. Chem Rev 108: 1171-1224. (Pubitemid 351638813)
67. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA,. 2009. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137: 1032-1046.
68. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, Jaenisch R, Sharp PA, Jacks T,. 2008. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132: 875-886. (Pubitemid 351312807)
69. Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST, Ghoshal K,. 2010a. TGFbeta-mediated upregulation of hepatic miR-181 promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 29: 1787-1797.
70. Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, Chen N, Sun F, Fan Q,. 2010b. CREB upregulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 38: 5366-5383.
71. Wu X, Xiao H,. 2009. miRNAs modulate drug response in tumor cells. Sci China C Life Sci 9: 797-801.
72. Wu Z, Asokan A, Samulski RJ,. 2006. Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Mol Ther 14: 316-327. (Pubitemid 44184972)
73. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, jia WH, Zhung SM,. 2010. Effects of microRNA-29 on apoptosis, tumorigenicity and prognosis of hepatocellular carcinoma. Hepatology 51: 836-845.
74. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH,. 2010a. MicroRNA-21 represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer. Clin Chim Acta 411: 11-12.
75. Zhang S, Chen L, Jung EJ, Calin GA,. 2010b. Targeting microRNAs with small molecules: From dream to reality. Clin Pharmacol Ther 87: 754-758.
76. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ,. 2008. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with Tamoxifen resistance in breast cancer. J Biol Chem 283: 31079-31086.